<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(9)</volume><submitter>den Braanker D</submitter><pubmed_abstract>Recurrence of proteinuria after kidney transplantation in primary focal segmental glomerulosclerosis (FSGS) is unpredictable. Several putative circulating permeability factors (CPFs) have been suggested, but none have been validated. A clinically relevant experimental model is required that demonstrates the presence of CPF(s) in patient material, to study CPF(s) and possibly predict recurrence in patients. We aimed to develop a FSGS-prone Thy-1.1 transgenic mouse model with accelerated proteinuria after injection of samples from patients with FSGS. The Thy-1.1 transgene was backcrossed into 5 mouse strains. The age of onset and severity of spontaneous proteinuria varied between the different genetic backgrounds. 129X1/SvThy-1.1 and 129S2/SvPasThy-1.1 mice displayed proteinuria at 4 weeks, </pubmed_abstract><journal>PloS one</journal><pagination>e0274959</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9499224</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Novel mouse strains to study circulating permeability factor(s) in primary focal segmental glomerulosclerosis.</pubmed_title><pmcid>PMC9499224</pmcid><pubmed_authors>Maas R</pubmed_authors><pubmed_authors>Nijenhuis T</pubmed_authors><pubmed_authors>van der Vlag J</pubmed_authors><pubmed_authors>Smeets B</pubmed_authors><pubmed_authors>den Braanker D</pubmed_authors><pubmed_authors>Deegens J</pubmed_authors><pubmed_authors>Wetzels J</pubmed_authors><pubmed_authors>Parr N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Novel mouse strains to study circulating permeability factor(s) in primary focal segmental glomerulosclerosis.</name><description>Recurrence of proteinuria after kidney transplantation in primary focal segmental glomerulosclerosis (FSGS) is unpredictable. Several putative circulating permeability factors (CPFs) have been suggested, but none have been validated. A clinically relevant experimental model is required that demonstrates the presence of CPF(s) in patient material, to study CPF(s) and possibly predict recurrence in patients. We aimed to develop a FSGS-prone Thy-1.1 transgenic mouse model with accelerated proteinuria after injection of samples from patients with FSGS. The Thy-1.1 transgene was backcrossed into 5 mouse strains. The age of onset and severity of spontaneous proteinuria varied between the different genetic backgrounds. 129X1/SvThy-1.1 and 129S2/SvPasThy-1.1 mice displayed proteinuria at 4 weeks, </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-18T20:53:06.658Z</modification><creation>2025-04-07T08:58:07.769Z</creation></dates><accession>S-EPMC9499224</accession><cross_references><pubmed>36137166</pubmed><doi>10.1371/journal.pone.0274959</doi></cross_references></HashMap>